Showing results (61-70 of 125) with videos related to

Sort By:
Pageof 13
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 19, 2014
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjectsTheodore R Johnson, Weiwei Tan, Lance Goulet, et al.
Bioorganic & Medicinal Chemistry|August 4, 2022
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitorsChristopher R Smith, Ruth Aranda, James G Christensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer modelsCathy C Zhang, Adam Pavlicek, Qin Zhang, et al.
Molecular Cancer Therapeutics|March 6, 2012
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitorHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Cancer Research|May 3, 2008
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitorsUltan McDermott, A John Iafrate, Nathanael S Gray, et al.
Molecular Cancer Therapeutics|January 7, 2012
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735Kenneth E Hook, Scott J Garza, Maruja E Lira, et al.
Genomics|February 26, 2013
Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatmentDonghui Huang, Dong-Wan Kim, Athanasios Kotsakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer PatientsCloud P Paweletz, Grace A Heavey, Yanan Kuang, et al.
Cancer Discovery|November 6, 2023
Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung AdenocarcinomaZhuxuan Li, Xueqian Zhuang, Chun-Hao Pan, et al.
Cancer Research|May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Pageof 13